Local view for "http://purl.org/linkedpolitics/eu/plenary/2002-07-02-Speech-2-232"
Predicate | Value (sorted: default) |
---|---|
rdf:type | |
dcterms:Date | |
dcterms:Is Part Of | |
dcterms:Language | |
lpv:document identification number |
"en.20020702.10.2-232"2
|
lpv:hasSubsequent | |
lpv:speaker | |
lpv:spokenAs | |
lpv:translated text |
"I should like to thank the Commissioner for his answer. In my view, Parliament has fought with him a successful battle towards a breakthrough in Doha on this score. He rejects a waiver, a moratorium or an exemption by way of solution, and we share his view on this.
Regarding Articles 30 and 31, he states that he intends to obtain support so that what we set out to do there can actually be achieved. Needless to say, we are aware in this House of the pressure of the United States and also of a number of Member States. The pharmaceutical industry is probably behind this. What is now up for discussion is whether it is possible, if use is made of Article 31 – and you are aware that we are now awaiting the legal opinion which we have requested as Parliament – to assume that the country that at some stage asks to import a licence from a different country, is allowed to take this decision regarding its own health situation at its own discretion. Indeed, many legal experts claim that, where Article 31 is concerned, this decision is no longer in the hands of the country in question but is to be taken at WTO level. We would like to have certainty in this area."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples